Psychedelic drug development can still benefit from the FDA Commissioner’s National Priority Review Voucher Pilot Program, though the CNPV designation was not given to Compass Pathways’ synthetic ...

Gilead Sciences has agreed to acquire Arcellx for $7.8 billion, the companies said today, in a deal intended to give the buyer full control of the buyout target’s lead candidate, a BCMA-directed ...

In this GEN webinar Ray Zhang, PhD, associate director, QC-Analytics at Franklin Biolabs will introduce the principles of mass photometry and highlight where it adds value across the analytical ...

Ahead of AGBT, Ultima Genomics launched its UG200 series touting smaller footprint, faster runtime, higher output, and lower pricing.

ArgenTag joins PacBio to enable instrument-free single-cell kits to support long-read isoform sequencing at single-cell ...

The FDA’s reversal of its earlier refusal to review mRNA-1010, the seasonal flu vaccine being developed by Moderna, accelerated a revival of Moderna shares that has been in progress over recent months ...

Nektar Therapeutics sees its stock nearly double after announcing positive Phase IIb data for its lead pipeline candidate, ...

Highly organized LNPs may resist releasing their cargo due to interactions between the positively-charged lipids and negatively-charged RNA.

Researchers suggest a vaccine could replace multiple jabs every year for seasonal respiratory infections and be on hand in the event of a new pandemic.

The data showed older people had less time from when elevated p-tau217 appeared until they began having symptoms compared to younger ones.

Jim Tananbaum, MD, Foresite Capital’s founder and CEO, and Michael Rome, PhD, the managing director who leads the firm’s therapeutics investing practice, discuss the firm’s approach to nurturing ...

The offering includes the full integration of the ADC technology platform, which will now be offered by Lonza as part of its advanced synthesis portfolio.